New fingerprick test and antibiotic aim to stop leprosy before it starts

NCT ID NCT06222372

Recruiting now Prevention Sponsor: Annemieke Geluk Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study in Bangladesh tests whether giving a single dose of the antibiotic rifampin to people who live with or near leprosy patients can prevent infection. Researchers will use a new fingerprick blood test to measure infection markers before and after treatment. The goal is to find an easy way to stop leprosy from spreading.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rifampin (antibiotic)
What this could lead to: If successful, this could provide a simple way to identify and treat people at risk of leprosy before they develop the disease, helping to stop its spread.
What could go wrong: This is an early-stage study focused on measuring infection markers, not preventing disease directly. The test and treatment may not work as hoped in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEPROSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multibacillary leprosy leprosy prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEPROSY

Contacts and locations

Locations

The Leprosy Mission International - Bangladesh
RECRUITING

Nilphamari, 5300, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.